<DOC>
	<DOCNO>NCT00003077</DOCNO>
	<brief_summary>RATIONALE : Omega-3 fatty acid use body energy tissue development may effective treatment patient advance cancer unable maintain body weight . PURPOSE : Phase I/II trial study effectiveness omega-3 fatty acid treat patient advanced cancer significant weight loss .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Treating Patients With Advanced Cancer Who Have Significant Weight Loss</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether omega-3 fatty acid reverse weight loss advance cancer patient cachexia . - Determine maximum tolerate dose ( MTD ) omega-3 fatty acid patient ( phase I complete 12/1999 ) . - Determine whether omega-3 fatty acid result antitumor response . OUTLINE : This randomize , stratify , dose escalation study . Patients stratify extent weight loss ( 2-5 percent great 5 percent past month ) . Patients receive omega-3 fatty acid orally two equal dos with/after breakfast lunch 4 month weight loss observe . Dose escalate cohort two patient , although dose escalation allow individual patient . The maximum tolerated dose ( MTD ) define high dose level great one-third patient treat , include escalated patient low dose , experience grade 3 bad toxicity ( phase I complete 12/1999 ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced cancer amenable curative therapy ( solid tumor hematologic malignancy eligible except primary metastatic brain tumor ) Cachexia ( weight loss least 2 percent within one month period ) PATIENT CHARACTERISTICS : Age : 18 Performance Status : CALBG 02 Life Expectancy : At least 2 month Hematopoietic : Granulocytes great 1,000/mm3 Platelet count great 75,000/mm3 Hemoglobin great 8 mg/dL Hepatic : AST le 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN Bilirubin less 1.5 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Cardiovascular : No congestive heart failure require diuretic within less 6 month No uncontrolled severe cardiovascular disease within less 6 month No myocardial infarction within less 6 month Other : Not pregnant contemplate pregnancy study Negative pregnancy test No uncontrolled hypercalcemia No metabolic disorder ( hyperthyroidism ) No poorly control diabetes No peripheral edema ascites require diuretic No enteric fistula , tracheobronchial fistula aspiration No esophageal bowel obstruction would preclude eat Free T4 within normal range No serious medical illness No psychosis No uncontrolled bacterial , viral , fungal infection No active uncontrolled duodenal ulcer Above laboratory value require unless bone marrow , liver , kidney , splenic involvement tumor document PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior concurrent chemotherapy allow Endocrine therapy : No concurrent steroid dronabinol megestrol acetate ( except adrenal failure ) Radiotherapy : No prior concurrent radiotherapy abdomen pelvis Surgery : Greater 3 week since major surgery Greater 1 week since minor surgery Other : No concurrent diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>